Akathisia is a movement disorder affecting the trunk and limbs, characterized by subjective and objective restlessness. Key signs include continual, repetitive rocking, leg shuffling, and fidgeting. Antipsychotic-induced akathisia is optimally managed by reducing the medication dose or switching to a second generation antipsychotic that is less prone to inducing akathisia. However, since medication changes are often not feasible, we review the available classes of rescue agents for akathisia symptoms. The fitting acronym, "B-CALM", which stands for Beta-blockers, Clonazepam, Anticholinergics, cLonidine and Mirtazapine, will assist prescribers in facile recall of evidence-based treatment options for akathisia. Pharmacological agents such as mianserin, trazodone, Vit B6, amantadine, gabapentin, and pregabalin have also been examined as treatment options for antipsychotic-induced akathisia. Although initial exploratory reports on these agents have been promising, the current evidence is insufficient. Akathisia has a good prognosis when managed early in the course of treatment. A variety of safe rescue agents are available for the management of this condition, however, current evidence best supports the use of propranolol and mirtazapine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374932 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Reassessing mirtazapine and akathisia: A case report on its efficacy in treating severe, treatment-resistant akathisia and a review of the evidence.
SAGE Open Med Case Rep
November 2024
Department of Psychiatry, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Article Synopsis
- * A 44-year-old man experienced severe, treatment-resistant akathisia from haloperidol, and standard treatments like benzodiazepines and benztropine were ineffective, leaving him in considerable distress.
- * Introducing mirtazapine at a low dose successfully improved his symptoms, as shown by a significant drop in the Barnes Akathisia Rating Scale score, showcasing mirtazapine's potential as an effective treatment for resistant cases of akathisia.
Chronic Cocaine Use and Parkinson's Disease: An Interpretative Model.
Int J Environ Res Public Health
August 2024
VP Dole Research Group, G. De Lisio Institute of Behavioural Sciences, Via di Pratale 3, 56121 Pisa, Italy.
Article Synopsis
- Cocaine use has become a significant public health issue, with roughly 24.6 million users globally and 1 million diagnosed with cocaine use disorder, according to the 2023 World Drug Report.
- While short-term effects of cocaine are well-documented, there is a lack of comprehensive data on its medium and long-term impacts, which suggest increased risks for cardiovascular issues and neurodegenerative diseases.
- The paper proposes that chronic cocaine use leads to neurobiological changes affecting neurotransmitter systems, particularly dopaminergic pathways, which may increase vulnerability to neurodegenerative disorders and highlights the need for further research to inform therapeutic interventions.
Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-analysis.
Schizophr Bull
June 2024
Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Background: Antipsychotics are the treatment of choice for schizophrenia, but they often induce akathisia. However, comparative efficacy of treatment strategies for akathisia remains unclear.
Design: We performed a systematic review and network meta-analyses (PROSPERO CRD42023450720).
The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties.
Psychother Psychosom
January 2024
Larry Alphs Consulting, Princeton, New Jersey, USA.
Article Synopsis
- The Extrapyramidal Symptom Rating Scale - Abbreviated (ESRS-A) is a streamlined tool for assessing drug-induced movement disorders, focusing on conditions like parkinsonism and tardive dyskinesia.
- Research shows that both the ESRS and ESRS-A have high inter-rater reliability and good concurrent validity when compared to other established scales, meaning different raters get consistent results.
- These tools are important for clinical research and practice, helping to identify and measure the severity of movement disorders caused by medications, especially antipsychotics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!